HR (95% CI) for developing breast cancer in relation to PAI-1 levels
| Quartiles of PAI-1 | P trend (median) | Continuous (for every SD increase) | ||||
|---|---|---|---|---|---|---|
| I | II | III | IV | |||
| All the women | ||||||
| Events/subcohort | 140/170 | 156/138 | 157/136 | 164/120 | ||
| HR* | -1- | 1.40 (1.00 to 1.95) | 1.44 (1.03 to 2.00) | 1.70 (1.21 to 2.39) | 0.0055 | 1.20 (1.06 to 1.35) |
| HR† | -1- | 1.41 (1.01 to 2.00) | 1.41 (1.00 to 1.99) | 1.66 (1.14 to 2.42) | 0.018 | 1.19 (1.04 to 1.36) |
| HR‡ | -1- | 1.41 (1.01 to 2.00) | 1.41 (0.99 to 1.99) | 1.66 (1.14 to 2.43) | 0.019 | 1.19 (1.04 to 1.37) |
| HR§ | -1- | 1.38 (0.98 to 1.95) | 1.41 (0.99 to 2.00) | 1.60 (1.07 to 2.40) | 0.035 | 1.21 (1.05 to 1.40) |
| Premenopausal status¶ | ||||||
| Events/subcohort | 82/82 | 78/65 | 56/67 | 50/46 | ||
| HR* | -1- | 1.22 (0.76 to 1.95) | 0.79 (0.47 to 1.31) | 0.92 (0.53 to 1.62) | 0.52 | 1.03 (0.83 to 1.27) |
| HR† | -1- | 1.13 (0.68 to 1.87) | 0.82 (0.48 to 1.41) | 1.02 (0.55 to 1.89) | 0.84 | 1.07 (0.85 to 1.34) |
| HR‡ | -1- | 1.13 (0.69 to 1.87) | 0.81 (0.47 to 1.40) | 0.98 (0.52 to 1.84) | 0.74 | 1.06 (0.84 to 1.33) |
| HR§ | -1- | 1.18 (0.70 to 1.98) | 0.82 (0.46 to 1.44) | 1.14 (0.57 to 2.27) | 0.94 | 1.17 (0.89 to 1.53) |
| Postmenopausal status¶ | ||||||
| Events/subcohort | 47/71 | 66/59 | 89/60 | 100/66 | ||
| HR* | -1- | 1.78 (1.06 to 3.00) | 2.36 (1.44 to 3.85) | 2.56 (1.56 to 4.20) | 0.0006 | 1.28 (1.09 to 1.51) |
| HR† | -1- | 1.79 (1.05 to 3.07) | 2.26 (1.35 to 3.78) | 2.35 (1.37 to 4.03) | 0.0070 | 1.24 (1.03 to 1.49) |
| HR‡ | -1- | 1.79 (1.04 to 3.07) | 2.26 (1.35 to 3.78) | 2.36 (1.37 to 4.06) | 0.0063 | 1.26 (1.04 to 1.53) |
| HR§ | -1- | 1.70 (0.98 to 2.94) | 2.15 (1.26 to 3.67) | 2.14 (1.20 to 3.82) | 0.024 | 1.22 (1.00 to 1.49) |
*Adjusted for age; stratified by centre.
†Adjusted for age, BMI, smoking habits, total physical activity, education, menopausal status, parity and age at menarche; stratified by centre.
‡As model 2, further adjusted for insulin, stratified by centre.
§As model 3, further adjusted for glucose, triglycerides and C reactive protein, stratified by centre; 20 participants are excluded from this analysis because of missing values for glucose or C reactive protein.
¶p for interaction (postmenopausal vs premenopausal): p=0.021 for model 2 and p=0.021 for model 3.
BMI, body mass index, PAI-1, plasminogen activator inhibitor-1.